Key statistics dashboard for Fractyl Health, Inc. (GUTS). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Stock Data
| Price | $0.56 |
| Market Cap | $89M |
| Enterprise Value | $102.8M |
| Beta | 1.19 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.51 |
| Price / Book | -53.60 |
| P/S | 0.00 |
| EV/EBITDA | -0.99 |
| EV/Sales | 0.00 |
| EV/FCF | -1.25 |
| P/FCF | -1.08 |
| Earnings Yield | -118.39% |
| FCF Yield | -92.38% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -1625.88% |
| Return on Assets | -128.88% |
| Return on Invested Capital | -120.27% |
| Return on Capital Employed | -129.67% |
Financial Health
| Current Ratio | 3.15 |
| Quick Ratio | 3.15 |
| Cash Ratio | 3.00 |
| Debt / Equity | -36.48 |
| Debt / Assets | 74.09% |
| Net Debt / EBITDA | -0.13 |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -7.47 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | -0.01 |
| Cash per share | 0.30 |
| FCF per share | -0.52 |
| Tangible Book Value per share | -0.01 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 0.67 |
Related companies: ADVM · ALXO · ARTV · ATYR · BMEA · DTIL · MGX
Explore sector: Healthcare · Biotechnology
More sections of GUTS: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks